Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation

Oncology Clinical Trial

Official title:

Randomized Phase II Study of Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation for Localized Spine Metastasis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04375891
• Other study ID #: 2018-KOT-001
• Status: Recruiting
• Phase: N/A
• Start date: May 22, 2020
• Est. completion date: May 2026

Study information

• Verified date: December 2023
• Source: Baptist Health South Florida
• Contact: Rupesh Kotecha, MD
• Phone: 786-596-2000
• Email: RupeshK[@]baptisthealth.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The spread of cancer to the spine is referred to as spine metastasis. Spine metastases are a common complication of cancer and are frequently associated with significant back pain. This study is being done to help improve treatment for back pain caused by spinal metastases by comparing the effectiveness of two standard treatments. These two treatments include radiation therapy (RT) alone versus radiation therapy combined with radiofrequency ablation, with or without vertebral augmentation (PVA/RFA). In addition to RT or RT with PVA/RFA, will be continued with current pain medications.

Description:

All supportive therapy for optimal medical care will be given during the study period at the discretion of the attending physician(s) within the parameters of the protocol and documented on each site's source documents as concomitant medication.

The study will be adequately powered with 52 patients (35 in the RT plus PVA/RFA arm and 17 in the RT arm). Assuming a 5% ineligibility rate, a death rate of 15%, and a patient non-compliance rate of 15%, the total sample size required would be 80 patients.

Patients will be stratified according to the tumor type (radioresistant [soft tissue sarcoma, melanoma, and renal cell carcinoma] versus other types). The treatment allocation scheme described by Zelen (1974) will be used because it balances patient factors. Within each stratum, patients will be randomized in a 2:1 ratio to either image-guided RT plus RFA/PVA or external beam RT alone.

The 2:1 randomization allocation will be used to accommodate increased demand for image-guided RT plus RFA/PVA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: May 2026
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patient must have localized spine metastasis from the T5 to L5 levels by an imaging study (bone scan, PET, CT, or MRI). Patients can have other visceral metastasis, and radioresistant tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are eligible.

• Zubrod Performance Status 0-3

• History/physical examination within 2 weeks prior to registration

• Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential; Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control;

• MRI (contrast is not required but strongly recommended) of the involved spine within 6 weeks prior to registration to determine the extent of the spine involvement;

• Numerical Rating Pain Scale within 1 week prior to registration; the patient must have a score on the Scale of = 5 for at least one of the planned sites for intervention. Documentation of the patient's initial pain score is required. Patients taking medication for pain at the time of registration are eligible.

• Patients with epidural compression are eligible provided that there is a = 3 mm gap between the spinal cord and the edge of the epidural lesion.

• Patients must provide study specific informed consent prior to study entry.

Exclusion Criteria:

• Histologies of myeloma, lymphoma, small-cell lung cancer, germ-cell tumor

• Non-ambulatory patients;

• Frank spinal cord compression or displacement or epidural compression within 3 mm of the spinal cord;

• Patients with rapid neurologic decline;

• Bony retropulsion causing neurologic abnormality;

• Prior radiation to the index spine

• Patients requiring immediate neurosurgical intervention

• Patients receiving concurrent chemotherapy

• Patients needing palliative to more than 2 sites of spinal disease in total

Related Conditions & MeSH terms

• Neoplasm Metastasis
• Oncology
• Spine Metastases

Intervention

Radiation:
• Radiation Therapy
30 Gy in 10 fractions of 3 Gy each
• Radiofrequency Ablation (RFA)
Radiofrequency Ablation (RFA) / Vertebral Augmentation

Locations

Country	Name	City	State
United States	Miami Cancer Institute at Baptist Health South Florida	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Baptist Health South Florida	Medtronic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in pain control	Change in pain control (as measured by the 11 point Numeric pain rating scale) as compared to conventional palliative radiotherapy alone.	3 months, 6, 12, 24 months
Secondary	Change in pain response	Change in the rapidity of pain response at the treated site(s) as compared to conventional Radiotherapy alone, as measured by the Numeric pain rating scale.	3 months, 6, 12, 24 months
Secondary	Measure increases in the duration of pain response	Measure increases in the duration of pain response at the treated site(s), as compared to conventional RT alone, as measured by the Numeric pain rating scale.	3 months, 6, 12, 24 months
Secondary	Number of adverse events	Number of adverse events between the two treatments according to the NCI Common Terminology Criteria for Adverse Events version 5.0.	3 months, 6, 12, 24 months
Secondary	Measure the potential benefit on quality of life	Measure the potential benefit of radiotherapy plus Vertebral Augmentation/Radiofrequency Ablation on change in and overall quality of life, as measured by the Functional Assessment of Cancer Therapy-General; in pain as measured by the Brief Pain Inventory; and in health utilities as measured by the EuroQol	3 months, 6, 12, 24 months

External Links

•   Miami Cancer Institute website